Cargando…

Associations between YKL-40 and markers of disease severity and death in patients with necrotizing soft-tissue infection

BACKGROUND: Necrotizing soft-tissue infection (NSTI) is a severe and fast-progressing bacterial infection. Prognostic biomarkers may provide valuable information in treatment guidance and decision-making, but none have provided sufficient robustness to have a clinical impact. YKL-40 may reflect the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hedetoft, Morten, Hansen, Marco Bo, Madsen, Martin Bruun, Johansen, Julia Sidenius, Hyldegaard, Ole
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502346/ https://www.ncbi.nlm.nih.gov/pubmed/34627195 http://dx.doi.org/10.1186/s12879-021-06760-x

Ejemplares similares

Hyperbaric oxygen treatment is associated with a decrease in cytokine levels in patients with necrotizing soft‐tissue infection
por: Hedetoft, Morten, et al.
Publicado: (2021)

Increase in the Complement Activation Product C4d and the Terminal Complement Complex sC5b-9 Is Associated with Disease Severity and a Fatal Outcome in Necrotizing Soft-Tissue Infection
por: Hedetoft, Morten, et al.
Publicado: (2021)

Hyperbaric oxygen treatment in the management of necrotising soft-tissue infections: results from a Danish nationwide registry study
por: Hedetoft, Morten, et al.
Publicado: (2023)

Incidence, comorbidity and mortality in patients with necrotising soft-tissue infections, 2005–2018: a Danish nationwide register-based cohort study
por: Hedetoft, Morten, et al.
Publicado: (2020)

Hyperbaric oxygen treatment impacts oxidative stress markers in patients with necrotizing soft-tissue infection
por: Hedetoft, Morten, et al.
Publicado: (2021)

Pentraxin-3 as a marker of disease severity and risk of death in patients with necrotizing soft tissue infections: a nationwide, prospective, observational study
por: Hansen, Marco Bo, et al.
Publicado: (2016)

Key pathways and genes that are altered during treatment with hyperbaric oxygen in patients with sepsis due to necrotizing soft tissue infection (HBOmic study)
por: Vinkel, Julie, et al.
Publicado: (2023)

SuPAR correlates with mortality and clinical severity in patients with necrotizing soft-tissue infections: results from a prospective, observational cohort study
por: Polzik, Peter, et al.
Publicado: (2019)

Investigating the Effects of Hyperbaric Oxygen Treatment in Necrotizing Soft Tissue Infection With Transcriptomics and Machine Learning (the HBOmic Study): Protocol for a Prospective Cohort Study With Data Validation
por: Vinkel, Julie, et al.
Publicado: (2022)

Complement Activation Is Associated With Mortality in Patients With Necrotizing Soft-Tissue Infections—A Prospective Observational Study
por: Kristensen, Markus Korsholm, et al.
Publicado: (2020)

Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2020)

Molecular profiling of tissue biopsies reveals unique signatures associated with streptococcal necrotizing soft tissue infections
por: Thänert, Robert, et al.
Publicado: (2019)

Risk Factors and Predictors of Mortality in Streptococcal Necrotizing Soft-tissue Infections: A Multicenter Prospective Study
por: Bruun, Trond, et al.
Publicado: (2020)

Plasma YKL-40: A BMI-Independent Marker of Type 2 Diabetes
por: Nielsen, Anders R., et al.
Publicado: (2008)

Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2021)

Discriminatory plasma biomarkers predict specific clinical phenotypes of necrotizing soft-tissue infections
por: Palma Medina, Laura M., et al.
Publicado: (2021)

Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities
por: Sørensen, Michala Skovlund, et al.
Publicado: (2021)

Serum YKL-40 and colorectal cancer
por: Cintin, C, et al.
Publicado: (1999)

YKL-40 tissue expression and plasma levels in patients with ovarian cancer
por: Høgdall, Estrid VS, et al.
Publicado: (2009)

Associations of Plasma Nitrite, l-Arginine and Asymmetric Dimethylarginine With Morbidity and Mortality in Patients With Necrotizing Soft Tissue Infections
por: Hansen, Marco B., et al.
Publicado: (2018)

Association between cytokine response, the LRINEC score and outcome in patients with necrotising soft tissue infection: a multicentre, prospective study
por: Hansen, Marco Bo, et al.
Publicado: (2017)

The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test
por: Dam Mygind, Naja, et al.
Publicado: (2016)

YKL-40 as a possible marker of neutrophilic asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2023)

Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease
por: Holmgaard, Dennis B, et al.
Publicado: (2013)

Genetic Architecture of Group A Streptococcal Necrotizing Soft Tissue Infections in the Mouse
por: Chella Krishnan, Karthickeyan, et al.
Publicado: (2016)

YKL-40 expression in soft-tissue sarcomas and atypical lipomatous tumors: An immunohistochemical study of 49 tumors
por: Harving, Mette L, et al.
Publicado: (2014)

Prognosis and Reclassification by YKL‐40 in Stable Coronary Artery Disease
por: Schroder, Jakob, et al.
Publicado: (2020)

YKL-40 and genetic status of CHI3L1 in a large group of asthmatics
por: Hansen, Jakob W., et al.
Publicado: (2015)

Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma
por: Iwamoto, Fabio M., et al.
Publicado: (2014)

YKL-40—A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?
por: Schultz, Nicolai A., et al.
Publicado: (2010)

YKL-40 correlates with the phenotype of asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer
por: Lehtomäki, Kaisa, et al.
Publicado: (2023)

Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer
por: Lehtomäki, Kaisa, et al.
Publicado: (2021)

Biomarkers of necrotising soft tissue infections: aspects of the innate immune response and effects of hyperbaric oxygenation—the protocol of the prospective cohort BIONEC study
por: Hansen, Marco Bo, et al.
Publicado: (2015)

Changes in Plasma IL-6, Plasma VEGF and Serum YKL-40 During Treatment with Etanercept and Methotrexate or Etanercept Alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
por: Knudsen, Lene Surland, et al.
Publicado: (2009)

Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease
por: Hellwig, Konstantin, et al.
Publicado: (2015)

YKL-40 as a new promising prognostic marker of severity in COVID infection
por: Schoneveld, Lauranne, et al.
Publicado: (2021)

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer
por: Schultz, Nicolai A., et al.
Publicado: (2013)

YKL-40 Protein Correlates with the Phenotype of Asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

Plasma YKL-40 in the spectrum of neurodegenerative dementia
por: Villar-Piqué, Anna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v0p8hge511ekioi4vh3s32pok8